Age-related differences in pharmacokinetics of phosphonoformate in cats.
Phosphonoformate (PFA) is a simple PPi analog which inhibits the activities of a variety of viral DNA polymerase, RNA polymerase, and reverse transcriptase enzymes. PFA is a topical and parenteral treatment for human herpesvirus infections and is currently in phase I trials for treatment of acquired immunodeficiency syndrome. Pharmacokinetic properties of PFA in young (growing) and adult specific-pathogen-free cats were compared. Mean PFA clearance from plasma was twofold higher in young cats (7.52 ml/min per kg of body weight) than in adult cats (3.70 ml/min per kg). Higher PFA clearance from plasma observed in young cats may result from higher renal clearance or enhanced accumulation of PFA in bone tissue of young versus adult cats. No plasma protein binding of PFA was observed. Mean oral bioavailability was 35% in young cats. These data indicate that age-related differences in PFA clearance from plasma occur in cats.
Swenson
C L
CL
Department of Veterinary Pathobiology, Ohio State University, Columbus 43210.
Sams
R A
RA
Polas
P J
PJ
Michael
D F
DF
Mathes
L E
LE
D000284:Administration, Oral; D000375:Aging / Q000378:metabolism*; D000818:Animals; D001682:Biological Availability; D002415:Cats; D017245:Foscarnet; D006207:Half-Life; D007275:Injections, Intravenous; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D011485:Protein Binding
D017245:Foscarnet; D010746:Phosphonoacetic Acid